Ignite Creation Date:
2024-05-05 @ 8:02 PM
Last Modification Date:
2024-10-26 @ 9:57 AM
Study NCT ID:
NCT00787137
Status:
TERMINATED
Last Update Posted:
2010-10-26
First Post:
2008-11-06
Brief Title:
Single Dose PG102 in Patients With Active Psoriatic Arthritis
Sponsor:
PanGenetics UK Limited
Organization:
PanGenetics UK Limited
Study Overview
Official Title:
A Randomised Double Blind Placebo Controlled Single Ascending Dose Phase I Study To Evaluate The Safety Tolerability And Pharmacokinetics Of PG102 Anti-CD40 Monoclonal Antibody In Patients With Active Psoriatic Arthritis
Status:
TERMINATED
Status Verified Date:
2010-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
poor recruitment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective is to evaluate the safety and tolerability of a single intravenous dose of PG102 in patients with psoriatic arthritis The secondary objectives are to evaluate how PG102 moves around the body and to explore its effects on the disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2007-001017-42 | EUDRACT_NUMBER | None | None |